The RESOUND trial tested successfully regorafenib—a VEGFR, PDGFR, and FGFR inhibitor—as a well-tolerated monotherapy for advanced or recurrent B2 or B3 thymomas and thymic carcinomas [128]. The gene discussed is KDR; the disease is thymic carcinoma.